Pashtoon Kasi: The surgery could now be the “adjuvant” piece

Pashtoon Kasi shared on LinkedIn:

“Here’s a provocative from one of my colleagues:
Instead of calling immunotherapy “adjuvant” or “neoadjuvant”, the surgery could now be the “adjuvant” piece.

More on immunotherapy 1st before surgery NEJM.

Enhancing pathways of immune responses can lead to increased cures.”

View the article attached to the post.
Source: Pashtoon Kasi/LinkedIn

Dr. Pashtoon Kasi is a medical oncologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Within his roles at Weill Cornell Medicine, he holds the positions of Director for Colorectal Cancer Research and Precision Medicine Director for Liquid Biopsy Research at the Englander Institute of Precision Medicine. Previously, Dr. Kasi served as an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of Iowa, following positions as an Assistant Professor of Medicine and Oncology at both the University of Iowa and Mayo Clinic.

His research primarily focuses on “liquid biopsies,” particularly circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). Dr. Kasi is also recognized as an author and editor of several significant books, including “Research: What, Why, and How: A Treatise from Researchers to Researchers” and “Impact of Circulating Tumor DNA (ctDNA) in Patients with Gastrointestinal Malignancies.” His scholarly contributions extend to over 100 publications in esteemed peer-reviewed journals.